REFERENCES
- Shulman L, Ost D. Managing infection in the critical care unit: how can infection control make the ICU safe? Crit Care Clin 2005; 21 ( 1): 111-128, ix.
- Fridkin SK. Increasing prevalence of antimicrobial resistance in inten-sive care units. Crit Care Med 2001; 29 (4 Suppl): N64–68.
- Low DE, Markovic MJ, Dowzicky MJ. Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU setting and different age groups: results from the tigecycline evaluation and Surveillance trial in North America. J Chemother 2009; 21 (1): 16–23.
- Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Antimicrobial sus-ceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test In-formation Collection Program (USA). Diagn Microbiol Infect Dis 2006; 56 (1): 57–62.
- Wang H, Chen M. Surveillance for antimicrobial resistance among clin-ical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002. Diagn Microbiol Infect Dis 2005; 51 (3): 201–208.
- WangChen M, Ni Y, Liu Y, Sun H, Yu Y, et al. Antimicrobial re-sistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents 2010; 35 (3): 227–234.
- Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; 20th informational supplement (June 2010 update).Document M100-520-U. Wayne, PA: CLSI; 2010.
- Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004; 24 (2): 111–118.
- Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: re-sults from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008; 30 (11): 2040–2050.
- Yan ZQ, Shen DX, Cao JR, Chen R, Wei X, Liu LP, et al. Suscepti-bility patterns and molecular epidemiology of multidrug-resistant Acineto-bacter baumannii strains from three military hospitals in China. Int J Antimicrob Agents 2010; 35 (3): 269–273.
- Jung S, Yu JK, Shin SH, Park KG, Jekarl DW, Han K, et al. False sus-ceptibility to amikacin by VITEK 2 in Acinetobacter baumann ii Harboring armA. Ann Clin Lab Sci 2010; 40 (2): 167–71.
- Xianghong. M, Li. X, Tieji. K, Mei. D, Hong. L, Bingyi S. Drug re-sistance analysis on ESBLs-producing Escherichia coli and Klebsiella pneu-moniae. Zhong Guo Shi Yan Zhen Duan 2006; 10 (1): 55–57.
- Chanawong A, M'Zali FH, Heritage J, Xiong JH, Hawkey PM. Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacte-riaceae in the People's Republic of China. Antimicrob Agents Chemother 2002; 46 (3): 630–637.
- Wang H, Kelkar S, Wu W, Chen M, Quinn JP. Clinical isolates of En-terobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China. Antimicrob Agents Chemother 2003; 47 (2): 790–793.